geranylgeranyl pyrophosphate

Geranylgeranyl pyrophosphate, a key metabolite in protein geranylgeranylation, serves as the universal precursor for diterpenoids, such as Paclitaxel. Its role in cancer research stems from this critical function.

Geranylgeranyl pyrophosphate tetrabutylammonium(1:2) is one of the endogenous cholesterol and intermediates produced by the mevalerate pathway. Geranylgeranyl pyrophosphate tetrabutylammonium(1:2) is the common precursor of diterpenoids, for example, Paclitaxel. It can be used for cancer research.

(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl dihydrogen diphosphate,tetrabutylammonium(1:1.5) is a common precursor of taxadiene such as Paclitaxel.

Geranylgeranyl Pyrophosphate triammonium (GGPP triammonium) is a metabolite involved in protein geranylgeranylation, modulating endothelial cell proliferation and apoptosis during mouse embryonic angiogenesis. GGPP triammonium amplifies T(reg) differentiation by increasing IL-2 expression, improving DSS-induced colitis, useful in cancer research.

Digeranyl bisphosphonate (DGBP) is a potent geranylgeranyl pyrophosphate (GGPP) synthase inhibitor that impedes the geranyl pyrophosphorylation of Rac1 and induces autophagy without causing apoptosis.

Geranyl pyrophosphate is an intermediate in the mevalonate pathway. It is formed from dimethylallyl pyrophosphate and isopentenyl pyrophosphate by geranyl pyrophosphate synthase. Geranyl pyrophosphate is used in the biosynthesis of farnesyl pyrophosphate , geranylgeranyl pyrophosphate , cholesterol, terpenes, and terpenoids.

hGGPPS-IN-2 is an analogue of C-2 substituted thienopyrimidinyl bisphosphonates (C2-ThP-BPs) and is a potent inhibitor of human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-2 targets multiple myeloma (MM) cells, induces selective apoptosis, and shows anti-myeloma effects in vivo. It has shown anti-myeloma effects in vivo.

Compound 13h (hGGPPS-IN-3) is a potent inhibitor of human geranylgeranyl pyrophosphate synthase (hGGPPS), characterized as a C-2-substituted thienopyrimidine-based bisphosphonate analogue (C2-ThP-BPs). It selectively induces apoptosis in multiple myeloma (MM) cells and demonstrates antimyeloma activity in vivo [1].